Big Pharma’s $300 Billion Patent Problem Fuels Biotech DealsBig Pharma’s $300 Billion Patent Problem Fuels Biotech DealsBig Pharma’s $300 Billion Patent Problem Fuels Biotech Deals 

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection. Key Takeaways: Big Pharma faces $300 billion in expiring drug patents through the decade. Total biopharma deal value […]
The post Big Pharma’s $300 Billion Patent Problem Fuels Biotech Deals appeared first on ETF Trends.